Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for Alopecia Areata Medical Dialogues Bureau19 March 2020 12:56 PM ISTBaricitinib is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
